Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO).
At the last ASCO GU Conference Malecare presented a poster and had published an abstract titled, “Understanding Prostate Cancer Survivorship Relative to Co-Habitation” (http://tinyurl.com/jqmluuf). The findings of this research contradicted the long-standing belief that men in a marriage lived longer because they were in a marriage. We concluded that we have to look for reasons unrelated to personal relationships and household composition to understand why married men diagnosed with prostate cancer hold a longevity advantage over single men!
At the upcoming ASCO Annual Meeting scheduled to be held in Chicago, Malecare has published additional research finds (J Clin Oncol 34, 2016 (suppl; abstr e16548)) showing that the utilization of treatments differs between heterosexual men and gay and bisexual men. We found that almost twice as many initially treated heterosexuals navigate towards advanced stage treatments, as do men who are gay or bisexual.
Additionally, Malecare’s Executive Director, Darryl Mitteldorf, is a co-investigator with other investigators from the University of Minnesota on a NCI funded project.
Malecare also recently received a patent for its design of a system to protect people from radiation treatment and diagnostics side effects.